Basic Information
| LncRNA/CircRNA Name | PVT1 |
| Synonyms | NA |
| Region | GRCh38_8:127794533-128101253 |
| Ensemble | ENSG00000249859 |
| Refseq | NR_003367 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | 5-Fluorouracil | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR, Western blot |
| Sample | Human GC cell lines SGC-7901, tumor, xenografs, adjacent normal tissues |
| Expression Pattern | up-regulated |
| Function Description | We confrmed that PVT1 can promote the progression of gastric cancer. PVT1 inhibited the apoptosis of GC cells, which may account for its promotion on GC. We confrmed that PVT1 can regulate the expression of Bcl2 and enhance drug-resistance of gastric cancer to 5-Fu. Kaplan-Meier analysis showed that patients with high PVT1 expression do not experience survival related benefts from 5- Fu based chemotherapy; instead, therapy containing no 5-Fu chemotherapy can improve the frst progression survival and overall survival of high PVT1 expression GC patients signifcantly. |
| Pubmed ID | 31205469 |
| Year | 2019 |
| Title | LncRNA PVT1 Mediates Antiapoptosis and 5-Fluorouracil Resistance via Increasing Bcl2 Expression in Gastric Cancer |
External Links
| Links for PVT1 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |